San Diego, California 92103


An efficacy and safety study of Gevokizumab in treating active ulcers of pyoderma gangrenosum.

Study summary:

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum.


Inclusion Criteria: - A clinical diagnosis of classic pyoderma gangrenosum - An active pyoderma gangrenosum ulcer - A willingness to use contraceptive methods to prevent pregnancy during the study Exclusion Criteria: - A clinical evidence of acute infected pyoderma gangrenosum - Active Hepatitis B, C, and postive Quantiferon TB test result - History of HIV - History of malignancy, clinically significant recurrent or chronic systemic infection - History of severe allergic or anaphylactic reaction to monoclonal antibodies - Washout periods for certain treatments applies. Protocol-defined inclusion/exclusion criteria may apply.



Primary Contact:

Principal Investigator
Michelle Pelle, M.D.
MedDerm Associates


Backup Contact:


Location Contact:

San Diego, California 92103
United States

Karla Anselmo, CRC
Phone: 619-243-7015

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.